NeRRe Therapeutics Ltd, which is developing neurokinin receptor antagonists for a range of diseases including pruritus, has appointed Ian Nicholson as chief business officer.
Mr Nicholson, who has more than 25 years of experience in the life science sector, will continue as chief executive of F2G Ltd and as an operating partner of Advent Life Sciences LLP. Advent is an investor in NeRRe Therapeutics. The appointment was announced on 18 March 2014.
Copyright 2014 Evernow Publishing Ltd